Dual therapy with tamsulosin and dutasteride is more effective than either agent alone in reducing the risk of progression in patients with benign prostatic hyperplasia (BPH), according to the findings of a four-year trial involving 4,800 men who received oral daily tamsulosin (0.4 mg), dutasteride (0.5 mg), or a combination of the two drugs.

Compared with tamsulosin monotherapy, the two-drug regimen reduced the relative risk of acute urinary retention (AUR) by 67.6% and BPH-related surgery by 70.6%, Claus Roehrborn, MD, and co-investigators reported in European Urology (2010;57:123-131).

Compared with dutasteride monotherapy, the combination treatment decreased the relative risk of AUR by 18.3% and BPH-related surgery by 31.1%.

Continue Reading